Abstract
Context
Although office-based opioid treatment with buprenorphine (OBOT-B) has been successfully implemented in primary care settings in the US, its use has not been reported in homeless patients.
Objective
To characterize the feasibility of OBOT-B in homeless relative to housed patients.
Design
A retrospective record review examining treatment failure, drug use, utilization of substance abuse treatment services, and intensity of clinical support by a nurse care manager (NCM) among homeless and housed patients in an OBOT-B program between August 2003 and October 2004. Treatment failure was defined as elopement before completing medication induction, discharge after medication induction due to ongoing drug use with concurrent nonadherence with intensified treatment, or discharge due to disruptive behavior.
Results
Of 44 homeless and 41 housed patients enrolled over 12 months, homeless patients were more likely to be older, nonwhite, unemployed, infected with HIV and hepatitis C, and report a psychiatric illness. Homeless patients had fewer social supports and more chronic substance abuse histories with a 3- to 6-fold greater number of years of drug use, number of detoxification attempts and percentage with a history of methadone maintenance treatment. The proportion of subjects with treatment failure for the homeless (21%) and housed (22%) did not differ (P = .94). At 12 months, both groups had similar proportions with illicit opioid use [Odds ratio (OR), 0.9 (95% CI, 0.5–1.7) P = .8], utilization of counseling (homeless, 46%; housed, 49%; P = .95), and participation in mutual-help groups (homeless, 25%; housed, 29%; P = .96). At 12 months, 36% of the homeless group was no longer homeless. During the first month of treatment, homeless patients required more clinical support from the NCM than housed patients.
Conclusions
Despite homeless opioid dependent patients’ social instability, greater comorbidities, and more chronic drug use, office-based opioid treatment with buprenorphine was effectively implemented in this population comparable to outcomes in housed patients with respect to treatment failure, illicit opioid use, and utilization of substance abuse treatment.
Similar content being viewed by others
References
US Department of Health and Human Services. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2004 National Survey on Drug Use & Health. Available at http://oas.samhsa.gov/NSDUH/2k4NSDUH/2k4results/2k4results.htm#ch2. Accessed July 11, 2006.
US Department of Health and Human Services. Substance Abuse and Mental Health Services Administration (SAMHSA). The DASIS Report: Non-Heroin Opiate Admissions, 2003. Results from the Drug and Alcohol Services Information System (DASIS). 2003. Available at http://oas.samhsa.gov/2k6/opiatesTX/opiatesTX.cfm. Accessed July 11, 2006.
National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43.
Johnson RE, Jaffe JH, and Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–55.
Ling W, Wesson DR, Charuvastra C, and Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401–7.
Ball JC and Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer—Berlin Heidelberg New York; 1991.
Joseph H, Stancliff S, and Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67:347–64.
O’Connor PG and Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000;133:40–54.
Institute of Medicine. Federal regulation of methadone treatment. Washington, DC: National Academy of Medicine; 1995.
Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, and Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290–7.
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–58.
Kakko J, Svanborg KD, Kreek MJ, and Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–8.
Fiellin DA and O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137:688–92.
Stein MD, Cioe P, and Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038–41.
Alford DP, Saitz R, LaBelle CT, and Samet JH. Buprenorphine initiation and maintenance in primary care: a successful interdisciplinary approach. J Gen Intern Med. 2004;19(suppl):103.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
Burt MR, Aron LY, Douglas T, Valente J, Lee E, and Iwen B. Homelessness: programs and the people they serve. Technical report of findings of the National Survey of Homeless Assistance Providers and Clients. 1999. Interagency Council on the Homeless.
Fischer PJ and Breakey WR. The epidemiology of alcohol, drug, and mental disorders among homeless persons. Am J Psychol. 1991;46:1115–28.
Stahler GJ and Cohen E. Homelessness and substance abuse in the 1990s. Contemp Drug Probl. 1995;22:169–92.
Koegel P, Sullivan G, Burnam A, Morton SC, and Wenzel S. Utilization of mental health and substance abuse services among homeless adults in Los Angeles. Med Care. 1999;37:306–17.
Hibbs JR, Benner L, Klugman L, et al. Mortality in a cohort of homeless adults in Philadelphia. N Engl J Med. 1994;331:304–9.
Hwang SW, Lebow JM, Bierer MF, O’Connell JJ, Orav J, and Brennan TA. Risk factors for death in homeless adults in Boston. Arch Int Med. 1998;158:1454–60.
Wright JD and Weber E. Homelessness and health. New York, NY: McGraw-Hill, Inc; 1987.
Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998–1999. Am J Public Health. 2001;91:1842–6.
Blanchon T, Boissonnas A, Vareseon I, and Vidal-Trecan G. Homelessness and high-dosage buprenorphine misuse. Subst Use Misuse. 2003;38:429–42.
Thomas L, Kelly M, and Cousineau M. Alcoholism and substance abuse. In: Brickner PW, Scharer LK, Conanan BA, Savarese M, and Scanlan BC, eds. Under the safety net: The health and social welfare of the homeless in the United States. New York, NY: W.W. Norton & Co.; 1990;204–14.
Song JY, Safaeian M, Strathdee SA, Vlahov D, and Celentano DD. The prevalence of homelessness among injection drug users with and without HIV infection. J Urban Health. 2000;77:678–87.
Galanter M, Dermatis H, Glickman L, et al. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat. 2004;26:313–8.
Kertesz SG, Horton NJ, Friedmann PD, Saitz R, and Samet JH. Slowing the revolving door: stabilization programs reduce homeless persons’ substance use after detoxification. J Subst Abuse Treat. 2003;24:197–207.
Milby JB, Schumacher JE, Raczynski JM, et al. Sufficient conditions for effective treatment of substance abusing homeless persons. Drug Alcohol Depend. 1996;43:39–47.
Shah NG, Celentano DD, Vlahov D, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS. 2000;14:2035–43.
Mistral W and Velleman R. Are practice nurses an underused resource for managing patients having problems with illicit drugs? J Subst Use. 1999;4:82–7.
SAS Institute Inc. SAS/STAT Software: Changes and Enhancements, Release 8.2. Cary, NC: SAS Institute Inc.; 2001.
Berwick DM. A user’s manual for the IOM’s ‘quality chasm’ report. Health Aff. 2002;21:80–90.
Acknowledgements
Preliminary results of this study were presented at the 28th annual meeting of the Society of General Internal Medicine in New Orleans on May 11–14, 2005, the 67th annual national meeting of the College on Problems of Drug Dependence in Orlando, FL on June 18–23, 2005, and at the 29th annual meeting of the Association for Medical Education and Research in Substance Abuse in Bethesda, MD on October 27–29, 2005. Data management was provided by Michael Winter MPH and Jacqueline Ashba MA, MPH, at the Data Coordinating Center, Boston University School of Public Health, Boston, MA. Support for these programs and their evaluation was provided by the Massachusetts Department of Public Health: Bureau of Substance Abuse Services and HIV/AIDS Bureau.
Potential Financial Conflicts of Interest
None disclosed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alford, D.P., LaBelle, C.T., Richardson, J.M. et al. Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting. J GEN INTERN MED 22, 171–176 (2007). https://doi.org/10.1007/s11606-006-0023-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-006-0023-1